Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352976 · ClinicalTrials.gov registry record · Phase 2
TBI Dose De-escalation for Fanconi Anemia
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00352976 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 83 participants.
The verdict
NCT00352976, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This is a single arm, total body irradiation (TBI) trial. All patients will be prescribed TBI 300 cGy with the goal of evaluating secondary endpoints.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mycophenolate Mofetil
- PROCEDURE Bone Marrow Transplantation
- PROCEDURE Total Body Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2006-05-18 |
| Est. Completion | 2020-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352976
The ClinicalTrials.gov registry entry for NCT00352976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00352976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352976 about?
NCT00352976 is a clinical study titled "TBI Dose De-escalation for Fanconi Anemia". This is a single arm, total body irradiation (TBI) trial. All patients will be prescribed TBI 300 cGy with the goal of evaluating secondary endpoints.
What is the current status of trial NCT00352976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2006-05-18. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT00352976?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mycophenolate Mofetil (DRUG), Bone Marrow Transplantation (PROCEDURE), Total Body Irradiation (PROCEDURE).
Who is sponsoring clinical trial NCT00352976?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.